<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00223080</url>
  </required_header>
  <id_info>
    <org_study_id>RV144</org_study_id>
    <secondary_id>HSRRB A-11048</secondary_id>
    <nct_id>NCT00223080</nct_id>
  </id_info>
  <brief_title>HIV Vaccine Trial in Thai Adults</brief_title>
  <official_title>A Phase III Trial of Aventis Pasteur Live Recombinant ALVAC-HIV (vCP1521) Priming With VaxGen gp120 B/E (AIDSVAX B/E) Boosting in HIV-uninfected Thai Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>U.S. Army Medical Research and Development Command</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>United States Army Medical Materiel Development Activity</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
    <collaborator>
      <agency>Armed Forces Research Institute of Medical Sciences, Thailand</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Walter Reed Army Institute of Research (WRAIR)</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
    <collaborator>
      <agency>MCM Vaccines B.V.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>VaxGen</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Emmes Company, LLC</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ministry of Health, Thailand</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Mahidol University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Royal Thai Army Medical Department</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tripler Army Medical Center</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
    <collaborator>
      <agency>Henry M. Jackson Foundation for the Advancement of Military Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>U.S. Army Medical Research and Development Command</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether immunizations with an integrated
      combination of ALVAC-HIV (vCP1521) boosted by AIDSVAX gp120 B/E prevent HIV infection in
      healthy Thai volunteers.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A vaccine for the prevention of HIV infection remains an urgent need as part of the efforts
      to control the HIV pandemic. In this phase III efficacy trial, a 'prime-boost' vaccine
      strategy is evaluated for prevention of infection and amelioration of disease course.
      ALVAC-HIV (vCP1521) from sanofi pasteur is given as the 'prime' vaccine at months 0, 1, 3 and
      6; AIDSVAX gp120 B/E from VaxGen is given as the 'boost' at months 3 and 6. This regimen will
      be given to 8,000 adult Thai subjects, while another 8,000 will be given placebos in a
      double-blinded, randomized manner. Following the completion of each subjects immunization
      phase, he/she will be followed for 3 years with clinic visits every 6 months with HIV
      testing, pre- and post-test counseling. Subjects who become HIV infected will be counseled,
      referred to HIV treatment facilities for management according to national guidelines, and
      offered enrollment in a protocol for extended follow-up.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2003</start_date>
  <completion_date type="Actual">June 2009</completion_date>
  <primary_completion_date type="Actual">July 2006</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Kaplan-Meier Estimate of HIV-1 Infection Rate in Intent to Treat Population</measure>
    <time_frame>42 Months</time_frame>
    <description>HIV-1 infection rate. Detection of HIV-1 infection was defined according to the HIV diagnostic algorithm utilizing serologic and nucleic acid technologies. Incidence of HIV infection was compared in the vaccine and placebo-recipient groups.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Vaccine Efficacy as Determined by Acquisition of Infection in the Per-protocol Population</measure>
    <time_frame>42 Months</time_frame>
    <description>Cumulative Number of HIV Infections. Detection of HIV-1 infection was defined according to the HIV diagnostic algorithm utilizing serologic and nucleic acid technologies. Incidence of HIV infection was compared in the vaccine and placebo-recipient groups.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in HIV-1 Viral Load in Volunteers Developing HIV Infection During the Trial for the MITT Population</measure>
    <time_frame>42 months</time_frame>
    <description>Log10 HIV-1 viral loads for diagnostic specimens for subjects with post-HIV infection. The trial quantitated HIV plasma viral load at the time of diagnosis and through the remainder of the follow-up period. Peri infection results were compared in vaccine and placebo recipients who became HIV-infected during the trial.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in HIV-1 Viral Load in Volunteers Developing HIV Infection During the Trial for the Per Protocol Population</measure>
    <time_frame>42 months</time_frame>
    <description>Log10 HIV-1 viral loads for diagnostic specimens for subjects with post-HIV infection. The trial quantitated HIV plasma viral load at the time of diagnosis and through the remainder of the follow-up period. Peri infection results were compared in vaccine and placebo recipients who became HIV-infected during the trial.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in CD4 T Cell Count in Volunteers Who Developed HIV Infection During the Trial for MITT Population</measure>
    <time_frame>42 weeks</time_frame>
    <description>Two CD4 cell counts were obtained (at the verification blood draw and the notification blood draw) and through the remainder of the follow-up period. Results were compared in vaccine and placebo recipients who became HIV-infected during the trial.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety Assessment (SAE's and AEs)</measure>
    <time_frame>Dose Interval 1: week 0, Dose Interval 2: Week 4, Dose Interval 3: Week 12, and Dose Interval 4: Week 24; every 6 months during 3 year f/u period</time_frame>
    <description>The intent-to-treat population is used for analysis of AEs and treatment emergent events are reported. Participant AE rates for all AEs, SAEs and treatment-related AEs are summarized</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in HIV Risk Behaviors Associated With Participation in the Vaccine Trial (MITT)</measure>
    <time_frame>Week 182</time_frame>
    <description>Self Report of Risk Behavior Status by Treatment and Time. Specifically, this is the responses to the question &quot;Do you think that your everyday behavior puts you at risk for HIV infection?&quot; Modified intent to treat population (MITT)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">16402</enrollment>
  <condition>HIV Infection</condition>
  <arm_group>
    <arm_group_label>Vaccine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>ALVAC-HIV vCP1521 + AIDSVAX will both be administered by the intramuscular route (preferably in the deltoid region) on weeks 0, 4, 12, and 24.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>ALVAC Placebo + AIDSVAX Placebo will be administered at week 12 and 24. ALVAC Placebo only was additionally administered at week 0 and 4.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ALVAC-HIV vCP1521 + AIDSVAX</intervention_name>
    <description>Combined dose of 600 μg (300 μg of each antigen), co-formulated and administered in alumi-um hydroxide gel at a dose of 600 μg/mL</description>
    <arm_group_label>Vaccine</arm_group_label>
    <other_name>ALVAC-HIV (vCP1521) &gt;106 CCID50 per 1 mL dose</other_name>
    <other_name>AIDSVAX® B/E</other_name>
    <other_name>Bivalent HIV gp120 vaccine subtype B (MN), and E (A244)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>ALVAC Placebo + AIDSVAX Placebo</intervention_name>
    <description>ALVAC carrier, supplied as a lyophilized product, without virus and Aluminum hydroxide adjuvant, 1.2 mL per vial, given as a 1 mL injection</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>ALVAC carrier lyophilized product without virus</other_name>
    <other_name>Aluminum hydroxide adjuvant</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Possession of the 13-digit Thai National ID card

          -  18-30 years of age (inclusive), male or female

          -  For women, a negative urine pregnancy test on the day of enrollment, as well as
             assurance that adequate birth control measures would be applied during the course of
             the injections and the 3 months after the last injection.

          -  Absence of systemic disease or immunodeficiency as determined by medical history and
             directed physical examination.

          -  Negative serology for HIV-1 infection within 45 days prior to enrollment.

          -  Availability and commitment for 3.5 years of participation.

          -  Able to understand the study (shown by receiving a passing score on the Test of
             Understanding administered under the screening protocol) and gave written informed
             consent.

          -  Enrollment in and referral from screening protocol, RV148

        Exclusion Criteria:

          -  Previous participation in any HIV vaccine trial (unless the volunteer could provide
             documentation that he/she received placebo).

          -  Active tuberculosis, other systemic disease process, or immunodeficiency as detected
             by medical history and directed physical examination that would, in the opinion of the
             investigator, impede compliance with study requirements or complicate the
             interpretation of adverse events.

          -  Any significant finding that in the opinion of the investigator would increase the
             risk of having an adverse outcome from participating in this study or might interfere
             with the volunteer's ability to successfully complete the study.

          -  Occupational or other responsibilities that would prevent completion of 3.5 years of
             participation in the study.

          -  History of anaphylaxis or other serious adverse reactions to vaccines, or allergies or
             reactions likely to be exacerbated by any component of the vaccine or placebo,
             including egg products and neomycin.

          -  Women breast-feeding or pregnant (positive pregnancy test) or planning to become
             pregnant during the 9-month window between study enrollment and 3-months after the
             last vaccination visit.

          -  Study site employees who were involved in the protocol and may have had direct access
             to trial-related data.

          -  Chronic use of therapies which may modify immune response, such as IV immune globulin
             and systemic corticosteroids (in doses of &gt; 20 mg prednisone equivalent for periods
             exceeding 10 days), and use of experimental drugs or vaccines.

          -  Receipt of a non-HIV vaccine or immune globulins within 14 days.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>30 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Supachai Rerks-Ngarm, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ministry of Health, Thailand</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ban Lamung District Hospital</name>
      <address>
        <city>Ban Lamung District</city>
        <state>Chon Buri</state>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Phan Tong District Hospital</name>
      <address>
        <city>Phan Tong District</city>
        <state>Chon Buri</state>
        <zip>20160</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sattahip District Hospital</name>
      <address>
        <city>Sattahip District</city>
        <state>Chon Buri</state>
        <zip>20180</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ao Udom Hospital</name>
      <address>
        <city>Sri Racha District</city>
        <state>Chon Buri</state>
        <zip>20230</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ban Chang District Hospital</name>
      <address>
        <city>Ban Chang District</city>
        <state>Rayong</state>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ban Khai District Hospital</name>
      <address>
        <city>Ban Khai District</city>
        <state>Rayong</state>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klaeng District Hospital</name>
      <address>
        <city>Klaeng District</city>
        <state>Rayong</state>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Provincial Health Office</name>
      <address>
        <city>Muang District</city>
        <state>Rayong</state>
        <zip>21000</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Thailand</country>
  </location_countries>
  <reference>
    <citation>Nitayaphan S, Pitisuttithum P, Karnasuta C, Eamsila C, de Souza M, Morgan P, Polonis V, Benenson M, VanCott T, Ratto-Kim S, Kim J, Thapinta D, Garner R, Bussaratid V, Singharaj P, el-Habib R, Gurunathan S, Heyward W, Birx D, McNeil J, Brown AE; Thai AIDS Vaccine Evaluation Group. Safety and immunogenicity of an HIV subtype B and E prime-boost vaccine combination in HIV-negative Thai adults. J Infect Dis. 2004 Aug 15;190(4):702-6. Epub 2004 Jul 20.</citation>
    <PMID>15272397</PMID>
  </reference>
  <reference>
    <citation>Karnasuta C, Paris RM, Cox JH, Nitayaphan S, Pitisuttithum P, Thongcharoen P, Brown AE, Gurunathan S, Tartaglia J, Heyward WL, McNeil JG, Birx DL, de Souza MS; Thai AIDS Vaccine Evaluation Group, Thailand. Antibody-dependent cell-mediated cytotoxic responses in participants enrolled in a phase I/II ALVAC-HIV/AIDSVAX B/E prime-boost HIV-1 vaccine trial in Thailand. Vaccine. 2005 Mar 31;23(19):2522-9.</citation>
    <PMID>15752839</PMID>
  </reference>
  <reference>
    <citation>Brown AE, Nitayaphan S. Foundations for a Phase III human immunodeficiency virus vaccine trial: A decade of Thai-U.S. Army collaborative research. Mil Med. 2004 Aug;169(8):588-93. Review.</citation>
    <PMID>15379068</PMID>
  </reference>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>September 13, 2005</study_first_submitted>
  <study_first_submitted_qc>September 13, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 22, 2005</study_first_posted>
  <results_first_submitted>October 24, 2016</results_first_submitted>
  <results_first_submitted_qc>December 29, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">October 19, 2018</results_first_posted>
  <last_update_submitted>April 10, 2019</last_update_submitted>
  <last_update_submitted_qc>April 10, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 24, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HIV Seronegativity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aluminum Hydroxide</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>16,402 subjects were randomized, 16,395 were infection free and assigned treatment groups</recruitment_details>
      <pre_assignment_details>16,402 individuals were randomly assigned to the 2 treatment arms. 7 individuals were identified as having human immunodeficiency virus (HIV) infection that was present pre-vaccination detected by polymerase chain reaction (PCR) amplification. These individuals were removed from the modified intent to treat (MITT) population.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Vaccine</title>
          <description>ALVAC-HIV vCP1521 + AIDSVAX will both be administered by the intramuscular route (preferably in the deltoid region) on weeks 0, 4, 12, and 24.
ALVAC-HIV vCP1521 + AIDSVAX: Combined dose of 600 μg (300 μg of each antigen), co-formulated and administered in alumi-um hydroxide gel at a dose of 600 μg/mL</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>ALVAC Placebo + AIDSVAX Placebo will be administered at week 12 and 24. ALVAC Placebo only was additionally administered at week 0 and 4.
ALVAC Placebo + AIDSVAX Placebo: ALVAC carrier, supplied as a lyophilized product, without virus and Aluminum hydroxide adjuvant, 1.2 mL per vial, given as a 1 mL injection</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8197"/>
                <participants group_id="P2" count="8198"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7401"/>
                <participants group_id="P2" count="7401"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="796"/>
                <participants group_id="P2" count="797"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="253"/>
                <participants group_id="P2" count="232"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Required contraindicated med</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Non-compliant</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Moved from study area</title>
              <participants_list>
                <participants group_id="P1" count="37"/>
                <participants group_id="P2" count="47"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="259"/>
                <participants group_id="P2" count="284"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="85"/>
                <participants group_id="P2" count="74"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Reason not provided</title>
              <participants_list>
                <participants group_id="P1" count="141"/>
                <participants group_id="P2" count="140"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Modified Intent to Treat (MITT) Population - those participants who were infection free at entry into the study</population>
      <group_list>
        <group group_id="B1">
          <title>Vaccine</title>
          <description>ALVAC-HIV vCP1521 + AIDSVAX will both be administered by the intramuscular route (preferably in the deltoid region) on weeks 0, 4, 12, and 24.
ALVAC-HIV vCP1521 + AIDSVAX: Combined dose of 600 μg (300 μg of each antigen), co-formulated and administered in alumi-um hydroxide gel at a dose of 600 μg/mL</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>ALVAC Placebo + AIDSVAX Placebo will be administered at week 12 and 24. ALVAC Placebo only was additionally administered at week 0 and 4.
ALVAC Placebo + AIDSVAX Placebo: ALVAC carrier, supplied as a lyophilized product, without virus and Aluminum hydroxide adjuvant, 1.2 mL per vial, given as a 1 mL injection</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="8197"/>
            <count group_id="B2" value="8198"/>
            <count group_id="B3" value="16395"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>18 - 20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2297"/>
                    <measurement group_id="B2" value="2246"/>
                    <measurement group_id="B3" value="4543"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>21 - 25</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3633"/>
                    <measurement group_id="B2" value="3708"/>
                    <measurement group_id="B3" value="7341"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>26 - 30</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2267"/>
                    <measurement group_id="B2" value="2244"/>
                    <measurement group_id="B3" value="4511"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3164"/>
                    <measurement group_id="B2" value="3167"/>
                    <measurement group_id="B3" value="6331"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5033"/>
                    <measurement group_id="B2" value="5031"/>
                    <measurement group_id="B3" value="10064"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Province</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Chon Buri</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4107"/>
                    <measurement group_id="B2" value="4107"/>
                    <measurement group_id="B3" value="8214"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rayong</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4090"/>
                    <measurement group_id="B2" value="4091"/>
                    <measurement group_id="B3" value="8181"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Marital status</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Single</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3353"/>
                    <measurement group_id="B2" value="3338"/>
                    <measurement group_id="B3" value="6691"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Married</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4110"/>
                    <measurement group_id="B2" value="4169"/>
                    <measurement group_id="B3" value="8279"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Divorced</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="602"/>
                    <measurement group_id="B2" value="541"/>
                    <measurement group_id="B3" value="1143"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Widowed</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50"/>
                    <measurement group_id="B2" value="64"/>
                    <measurement group_id="B3" value="114"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Separated</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="82"/>
                    <measurement group_id="B2" value="86"/>
                    <measurement group_id="B3" value="168"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Number of sex partners</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1864"/>
                    <measurement group_id="B2" value="1801"/>
                    <measurement group_id="B3" value="3665"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5428"/>
                    <measurement group_id="B2" value="5495"/>
                    <measurement group_id="B3" value="10923"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt; 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="619"/>
                    <measurement group_id="B2" value="620"/>
                    <measurement group_id="B3" value="1239"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Did not answer</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="280"/>
                    <measurement group_id="B2" value="273"/>
                    <measurement group_id="B3" value="553"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing data</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Risk group</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3865"/>
                    <measurement group_id="B2" value="3924"/>
                    <measurement group_id="B3" value="7789"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Medium</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2369"/>
                    <measurement group_id="B2" value="2292"/>
                    <measurement group_id="B3" value="4661"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1963"/>
                    <measurement group_id="B2" value="1982"/>
                    <measurement group_id="B3" value="3945"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Kaplan-Meier Estimate of HIV-1 Infection Rate in Intent to Treat Population</title>
        <description>HIV-1 infection rate. Detection of HIV-1 infection was defined according to the HIV diagnostic algorithm utilizing serologic and nucleic acid technologies. Incidence of HIV infection was compared in the vaccine and placebo-recipient groups.</description>
        <time_frame>42 Months</time_frame>
        <population>Modified Intent-to-Treat (MITT) Population: those participants who were infection free at entry into the study</population>
        <group_list>
          <group group_id="O1">
            <title>Vaccine</title>
            <description>ALVAC-HIV vCP1521 + AIDSVAX will both be administered by the intramuscular route (preferably in the deltoid region) on weeks 0, 4, 12, and 24.
ALVAC-HIV vCP1521 + AIDSVAX: Combined dose of 600 μg (300 μg of each antigen), co-formulated and administered in alumi-um hydroxide gel at a dose of 600 μg/mL</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>ALVAC Placebo + AIDSVAX Placebo will be administered at week 12 and 24. ALVAC Placebo only was additionally administered at week 0 and 4.
ALVAC Placebo + AIDSVAX Placebo: ALVAC carrier, supplied as a lyophilized product, without virus and Aluminum hydroxide adjuvant, 1.2 mL per vial, given as a 1 mL injection</description>
          </group>
        </group_list>
        <measure>
          <title>Kaplan-Meier Estimate of HIV-1 Infection Rate in Intent to Treat Population</title>
          <description>HIV-1 infection rate. Detection of HIV-1 infection was defined according to the HIV diagnostic algorithm utilizing serologic and nucleic acid technologies. Incidence of HIV infection was compared in the vaccine and placebo-recipient groups.</description>
          <population>Modified Intent-to-Treat (MITT) Population: those participants who were infection free at entry into the study</population>
          <units>Percetage of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8197"/>
                <count group_id="O2" value="8198"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>12 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.15" lower_limit="0.07" upper_limit="0.24"/>
                    <measurement group_id="O2" value="0.38" lower_limit="0.24" upper_limit="0.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.41" lower_limit="0.27" upper_limit="0.55"/>
                    <measurement group_id="O2" value="0.64" lower_limit="0.46" upper_limit="0.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>36 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.58" lower_limit="0.41" upper_limit="0.75"/>
                    <measurement group_id="O2" value="0.84" lower_limit="0.63" upper_limit="1.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>42 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.68" lower_limit="0.49" upper_limit="0.87"/>
                    <measurement group_id="O2" value="0.96" lower_limit="0.74" upper_limit="1.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Vaccine Efficacy as Determined by Acquisition of Infection in the Per-protocol Population</title>
        <description>Cumulative Number of HIV Infections. Detection of HIV-1 infection was defined according to the HIV diagnostic algorithm utilizing serologic and nucleic acid technologies. Incidence of HIV infection was compared in the vaccine and placebo-recipient groups.</description>
        <time_frame>42 Months</time_frame>
        <population>Per-protocol population: The per-protocol analysis is restricted to the individuals who were infection-free at the completion of vaccination and who received a timely set of 4 vaccinations.</population>
        <group_list>
          <group group_id="O1">
            <title>Vaccine</title>
            <description>ALVAC-HIV vCP1521 + AIDSVAX will both be administered by the intramuscular route (preferably in the deltoid region) on weeks 0, 4, 12, and 24.
ALVAC-HIV vCP1521 + AIDSVAX: Combined dose of 600 μg (300 μg of each antigen), co-formulated and administered in alumi-um hydroxide gel at a dose of 600 μg/mL</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>ALVAC Placebo + AIDSVAX Placebo will be administered at week 12 and 24. ALVAC Placebo only was additionally administered at week 0 and 4.
ALVAC Placebo + AIDSVAX Placebo: ALVAC carrier, supplied as a lyophilized product, without virus and Aluminum hydroxide adjuvant, 1.2 mL per vial, given as a 1 mL injection</description>
          </group>
        </group_list>
        <measure>
          <title>Vaccine Efficacy as Determined by Acquisition of Infection in the Per-protocol Population</title>
          <description>Cumulative Number of HIV Infections. Detection of HIV-1 infection was defined according to the HIV diagnostic algorithm utilizing serologic and nucleic acid technologies. Incidence of HIV infection was compared in the vaccine and placebo-recipient groups.</description>
          <population>Per-protocol population: The per-protocol analysis is restricted to the individuals who were infection-free at the completion of vaccination and who received a timely set of 4 vaccinations.</population>
          <units>Percentage of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6176"/>
                <count group_id="O2" value="6366"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>12 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.08" lower_limit="0.01" upper_limit="0.15"/>
                    <measurement group_id="O2" value="0.25" lower_limit="0.13" upper_limit="0.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.36" lower_limit="0.21" upper_limit="0.51"/>
                    <measurement group_id="O2" value="0.49" lower_limit="0.32" upper_limit="0.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>36 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.52" lower_limit="0.34" upper_limit="0.71"/>
                    <measurement group_id="O2" value="0.70" lower_limit="0.49" upper_limit="0.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>42 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.59" lower_limit="0.40" upper_limit="0.78"/>
                    <measurement group_id="O2" value="0.80" lower_limit="0.58" upper_limit="1.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in CD4 T Cell Count in Volunteers Who Developed HIV Infection During the Trial for MITT Population</title>
        <description>Two CD4 cell counts were obtained (at the verification blood draw and the notification blood draw) and through the remainder of the follow-up period. Results were compared in vaccine and placebo recipients who became HIV-infected during the trial.</description>
        <time_frame>42 weeks</time_frame>
        <population>Prior to the analysis, the SAP identified the MITT as those participants who were infection free at entry into the study. Although individuals were screened for HIV antibody prior to entry, individuals identified by laboratory examination of PCR assessments of blinded pre-randomization specimens that were performed subsequent to entry were excluded</population>
        <group_list>
          <group group_id="O1">
            <title>Vaccine</title>
            <description>ALVAC-HIV vCP1521 + AIDSVAX will both be administered by the intramuscular route (preferably in the deltoid region) on weeks 0, 4, 12, and 24.
ALVAC-HIV vCP1521 + AIDSVAX: Combined dose of 600 μg (300 μg of each antigen), co-formulated and administered in alumi-um hydroxide gel at a dose of 600 μg/mL</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>ALVAC Placebo + AIDSVAX Placebo will be administered at week 12 and 24. ALVAC Placebo only was additionally administered at week 0 and 4.
ALVAC Placebo + AIDSVAX Placebo: ALVAC carrier, supplied as a lyophilized product, without virus and Aluminum hydroxide adjuvant, 1.2 mL per vial, given as a 1 mL injection</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in CD4 T Cell Count in Volunteers Who Developed HIV Infection During the Trial for MITT Population</title>
          <description>Two CD4 cell counts were obtained (at the verification blood draw and the notification blood draw) and through the remainder of the follow-up period. Results were compared in vaccine and placebo recipients who became HIV-infected during the trial.</description>
          <population>Prior to the analysis, the SAP identified the MITT as those participants who were infection free at entry into the study. Although individuals were screened for HIV antibody prior to entry, individuals identified by laboratory examination of PCR assessments of blinded pre-randomization specimens that were performed subsequent to entry were excluded</population>
          <units>cells / µL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
                <count group_id="O2" value="73"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>1st verification</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="565.4" spread="43.5"/>
                    <measurement group_id="O2" value="566.7" spread="26.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Notification</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="539.6" spread="37.1"/>
                    <measurement group_id="O2" value="570.6" spread="29.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Changes in HIV-1 Viral Load in Volunteers Developing HIV Infection During the Trial for the MITT Population</title>
        <description>Log10 HIV-1 viral loads for diagnostic specimens for subjects with post-HIV infection. The trial quantitated HIV plasma viral load at the time of diagnosis and through the remainder of the follow-up period. Peri infection results were compared in vaccine and placebo recipients who became HIV-infected during the trial.</description>
        <time_frame>42 months</time_frame>
        <population>Modified Intent-to-Treat (MITT) Population: those participants who were infection free at entry into the study</population>
        <group_list>
          <group group_id="O1">
            <title>Vaccine</title>
            <description>ALVAC-HIV vCP1521 + AIDSVAX will both be administered by the intramuscular route (preferably in the deltoid region) on weeks 0, 4, 12, and 24.
ALVAC-HIV vCP1521 + AIDSVAX: Combined dose of 600 μg (300 μg of each antigen), co-formulated and administered in alumi-um hydroxide gel at a dose of 600 μg/mL</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>ALVAC Placebo + AIDSVAX Placebo will be administered at week 12 and 24. ALVAC Placebo only was additionally administered at week 0 and 4.
ALVAC Placebo + AIDSVAX Placebo: ALVAC carrier, supplied as a lyophilized product, without virus and Aluminum hydroxide adjuvant, 1.2 mL per vial, given as a 1 mL injection</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in HIV-1 Viral Load in Volunteers Developing HIV Infection During the Trial for the MITT Population</title>
          <description>Log10 HIV-1 viral loads for diagnostic specimens for subjects with post-HIV infection. The trial quantitated HIV plasma viral load at the time of diagnosis and through the remainder of the follow-up period. Peri infection results were compared in vaccine and placebo recipients who became HIV-infected during the trial.</description>
          <population>Modified Intent-to-Treat (MITT) Population: those participants who were infection free at entry into the study</population>
          <units>log [HIV-1 viral load (unitless)]</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
                <count group_id="O2" value="73"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>First positive serology</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.379" spread="0.127"/>
                    <measurement group_id="O2" value="4.187" spread="0.101"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3-weeks post identificaiton</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.229" spread="0.130"/>
                    <measurement group_id="O2" value="4.235" spread="0.095"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>~6-weeks post identification</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.274" spread="0.125"/>
                    <measurement group_id="O2" value="4.167" spread="0.104"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Changes in HIV-1 Viral Load in Volunteers Developing HIV Infection During the Trial for the Per Protocol Population</title>
        <description>Log10 HIV-1 viral loads for diagnostic specimens for subjects with post-HIV infection. The trial quantitated HIV plasma viral load at the time of diagnosis and through the remainder of the follow-up period. Peri infection results were compared in vaccine and placebo recipients who became HIV-infected during the trial.</description>
        <time_frame>42 months</time_frame>
        <population>Per-protocol population: The per-protocol analysis is restricted to the individuals who were infection-free at the completion of vaccination and who received a timely set of 4 vaccinations.</population>
        <group_list>
          <group group_id="O1">
            <title>Vaccine</title>
            <description>ALVAC-HIV vCP1521 + AIDSVAX will both be administered by the intramuscular route (preferably in the deltoid region) on weeks 0, 4, 12, and 24.
ALVAC-HIV vCP1521 + AIDSVAX: Combined dose of 600 μg (300 μg of each antigen), co-formulated and administered in alumi-um hydroxide gel at a dose of 600 μg/mL</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>ALVAC Placebo + AIDSVAX Placebo will be administered at week 12 and 24. ALVAC Placebo only was additionally administered at week 0 and 4.
ALVAC Placebo + AIDSVAX Placebo: ALVAC carrier, supplied as a lyophilized product, without virus and Aluminum hydroxide adjuvant, 1.2 mL per vial, given as a 1 mL injection</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in HIV-1 Viral Load in Volunteers Developing HIV Infection During the Trial for the Per Protocol Population</title>
          <description>Log10 HIV-1 viral loads for diagnostic specimens for subjects with post-HIV infection. The trial quantitated HIV plasma viral load at the time of diagnosis and through the remainder of the follow-up period. Peri infection results were compared in vaccine and placebo recipients who became HIV-infected during the trial.</description>
          <population>Per-protocol population: The per-protocol analysis is restricted to the individuals who were infection-free at the completion of vaccination and who received a timely set of 4 vaccinations.</population>
          <units>log [HIV-1 viral load (unitless)]</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
                <count group_id="O2" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>First positive serology</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.307" spread="0.154"/>
                    <measurement group_id="O2" value="4.153" spread="0.136"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3-weeks post identificaiton</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.128" spread="0.161"/>
                    <measurement group_id="O2" value="4.276" spread="0.118"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>~6-weeks post identification</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.280" spread="0.152"/>
                    <measurement group_id="O2" value="4.143" spread="0.143"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Safety Assessment (SAE's and AEs)</title>
        <description>The intent-to-treat population is used for analysis of AEs and treatment emergent events are reported. Participant AE rates for all AEs, SAEs and treatment-related AEs are summarized</description>
        <time_frame>Dose Interval 1: week 0, Dose Interval 2: Week 4, Dose Interval 3: Week 12, and Dose Interval 4: Week 24; every 6 months during 3 year f/u period</time_frame>
        <population>intent-to-treat population</population>
        <group_list>
          <group group_id="O1">
            <title>Vaccine</title>
            <description>ALVAC-HIV vCP1521 + AIDSVAX will both be administered by the intramuscular route (preferably in the deltoid region) on weeks 0, 4, 12, and 24.
ALVAC-HIV vCP1521 + AIDSVAX: Combined dose of 600 μg (300 μg of each antigen), co-formulated and administered in alumi-um hydroxide gel at a dose of 600 μg/mL</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>ALVAC Placebo + AIDSVAX Placebo will be administered at week 12 and 24. ALVAC Placebo only was additionally administered at week 0 and 4.
ALVAC Placebo + AIDSVAX Placebo: ALVAC carrier, supplied as a lyophilized product, without virus and Aluminum hydroxide adjuvant, 1.2 mL per vial, given as a 1 mL injection</description>
          </group>
        </group_list>
        <measure>
          <title>Safety Assessment (SAE's and AEs)</title>
          <description>The intent-to-treat population is used for analysis of AEs and treatment emergent events are reported. Participant AE rates for all AEs, SAEs and treatment-related AEs are summarized</description>
          <population>intent-to-treat population</population>
          <units>adverse events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8197"/>
                <count group_id="O2" value="8198"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>30-day post dose interval 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1277"/>
                    <measurement group_id="O2" value="1336"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>30-day post dose interval 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="816"/>
                    <measurement group_id="O2" value="860"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>30-day post dose interval 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="614"/>
                    <measurement group_id="O2" value="597"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>30-day post dose interval 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="599"/>
                    <measurement group_id="O2" value="630"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>All treatment emergent</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5627"/>
                    <measurement group_id="O2" value="5685"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in HIV Risk Behaviors Associated With Participation in the Vaccine Trial (MITT)</title>
        <description>Self Report of Risk Behavior Status by Treatment and Time. Specifically, this is the responses to the question &quot;Do you think that your everyday behavior puts you at risk for HIV infection?&quot; Modified intent to treat population (MITT)</description>
        <time_frame>Week 182</time_frame>
        <population>Prior to the analysis, the SAP identified the MITT as those participants who were infection free at entry into the study. Although individuals were screened for HIV antibody prior to entry, individuals identified by laboratory examination of PCR assessments of blinded pre-randomization specimens that were performed subsequent to entry were excluded</population>
        <group_list>
          <group group_id="O1">
            <title>Vaccine</title>
            <description>ALVAC-HIV vCP1521 + AIDSVAX will both be administered by the intramuscular route (preferably in the deltoid region) on weeks 0, 4, 12, and 24.
ALVAC-HIV vCP1521 + AIDSVAX: Combined dose of 600 μg (300 μg of each antigen), co-formulated and administered in alumi-um hydroxide gel at a dose of 600 μg/mL</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>ALVAC Placebo + AIDSVAX Placebo will be administered at week 12 and 24. ALVAC Placebo only was additionally administered at week 0 and 4.
ALVAC Placebo + AIDSVAX Placebo: ALVAC carrier, supplied as a lyophilized product, without virus and Aluminum hydroxide adjuvant, 1.2 mL per vial, given as a 1 mL injection</description>
          </group>
        </group_list>
        <measure>
          <title>Change in HIV Risk Behaviors Associated With Participation in the Vaccine Trial (MITT)</title>
          <description>Self Report of Risk Behavior Status by Treatment and Time. Specifically, this is the responses to the question &quot;Do you think that your everyday behavior puts you at risk for HIV infection?&quot; Modified intent to treat population (MITT)</description>
          <population>Prior to the analysis, the SAP identified the MITT as those participants who were infection free at entry into the study. Although individuals were screened for HIV antibody prior to entry, individuals identified by laboratory examination of PCR assessments of blinded pre-randomization specimens that were performed subsequent to entry were excluded</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7399"/>
                <count group_id="O2" value="7395"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="702"/>
                    <measurement group_id="O2" value="763"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6223"/>
                    <measurement group_id="O2" value="6130"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Don't know/Not sure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="473"/>
                    <measurement group_id="O2" value="502"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing value</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>For serious adverse events - anytime after the first vaccination until final follow-up at week 184. For other adverse events - total post-injection reaction severity</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Vaccine</title>
          <description>ALVAC-HIV vCP1521 + AIDSVAX will both be administered by the intramuscular route (preferably in the deltoid region) on weeks 0, 4, 12, and 24.
ALVAC-HIV vCP1521 + AIDSVAX: Combined dose of 600 μg (300 μg of each antigen), co-formulated and administered in alumi-um hydroxide gel at a dose of 600 μg/mL</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>ALVAC Placebo + AIDSVAX Placebo will be administered at week 12 and 24. ALVAC Placebo only was additionally administered at week 0 and 4.
ALVAC Placebo + AIDSVAX Placebo: ALVAC carrier, supplied as a lyophilized product, without virus and Aluminum hydroxide adjuvant, 1.2 mL per vial, given as a 1 mL injection</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="85" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="75" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1175" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="1219" subjects_at_risk="8198"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Anaemia of pregnancy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Autoimmune thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Haemorrhagic anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Idiopathic thrombocytopenic purpura</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8198"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Cardiac valve disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Cardio-respiratory arrest</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Cardiomegaly</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Congestive cardiomyopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Extrasystoles</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Mitral valve stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Myocarditis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Ventricular extrasystoles</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Wolff-Parkinson-White syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8198"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial septal defect</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Cleft lip</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Cleft lip and palate</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Cleft palate</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Congenital anomaly</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Congenital heart valve disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Congenital inguinal hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Congenital megacolon</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Congenital skin disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Ebstein's anomaly</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Familial periodic paralysis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Foetal cystic hygroma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Glucose-6-phosphate dehydrogenase deficiency</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Hydrocele</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Limb malformation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Multiple congenital abnormalities</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Patent ductus arteriosus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Polydactyly</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Thyroglossal cyst</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Transposition of the great vessels</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Trisomy 21</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Urachal abnormality</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Ventricular septal defect</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="8198"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Auricular perichondritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Vertigo positional</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8198"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Adrenal insufficiency</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Goitre</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Hyperthyroidism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Thyrotoxic crisis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Thyrotoxic periodic paralysis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8198"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Photokeratitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Ulcerative keratitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8198"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal hernia obstructive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Abdominal pain lower</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Alcoholic pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Anal fissure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Anal polyp</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Appendicitis perforated</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Duodenal ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Duodenal ulcer haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Enteritis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Enterocolitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Food poisoning</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Gastritis alcoholic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Gastritis alcoholic haemorrhagic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Gastritis haemorrhagic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Gastroduodenitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Gastroduodenitis haemorrhagic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Haemorrhoidal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Inguinal hernia, obstructive</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Oesophageal ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Pancreatitis acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Peptic ulcer</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Peptic ulcer perforation</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Upper gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Volvulus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8198"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Drowning</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Electrocution</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Foreign body reaction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Lipogranuloma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Sudden death</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Cholangitis acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Cholecystitis chronic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Gallbladder polyp</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Hepatitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Hepatitis alcoholic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Hepatitis fulminant</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Jaundice cholestatic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Post cholecystectomy syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8198"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Allergy to arthropod bite</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Allergy to arthropod sting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Anaphylactic reaction</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Anaphylactic shock</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Drug hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Food allergy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Immune reconstitution syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8198"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abortion infected</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Abscess jaw</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Abscess limb</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Abscess neck</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Abscess oral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Acute sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Acute tonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Amoebic dysentery</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Anal abscess</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Anogenital warts</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="54" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="61" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Bacterial labyrinthitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Bacterial sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Bartholin's abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Breast abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Chronic tonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Dengue fever</sub_title>
                <counts group_id="E1" subjects_affected="57" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="45" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Dermatitis infected</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Diarrhoea infectious</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Disseminated tuberculosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Endocarditis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Endometritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Endometritis decidual</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Gastroenteritis bacterial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Giardiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Hepatitis A</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Hepatitis B</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Hepatitis viral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Hookworm infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Infected bites</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Infected cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Infected skin ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Infection in an immunocompromised host</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Leptospirosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Liver abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Lobar pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Lymph node tuberculosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Malaria</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Measles</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Meningitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Meningitis aseptic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Meningitis bacterial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Meningitis tuberculous</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Meningitis viral</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Mumps</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Murine typhus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Muscle abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Orchitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Osteomyelitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Osteomyelitis chronic</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Paronychia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Pelvic inflammatory disease</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Perineal infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Periorbital cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Peritonsillar abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Pharyngitis streptococcal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Pharyngotonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Plasmodium falciparum infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Pneumocystis jiroveci pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Pneumonia bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Pneumonia measles</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Pneumonia primary atypical</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Post procedural infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Postoperative wound infection</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Pulmonary tuberculosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Pyelonephritis acute</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Pyomyositis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Rickettsiosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Rubella</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Salmonellosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Salpingitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Scrub typhus</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Sialoadenitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Subcutaneous abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Tonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Tooth abscess</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Tuberculosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Tuberculous pleurisy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Typhoid fever</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Vaginal cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Varicella</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Viral skin infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Wound infection</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Penetrating abdominal trauma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Poisoning deliberate</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Testicular injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Ulna fracture</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Urinary bladder rupture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8198"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Abdominal injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Accident</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Accident at home</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Accident at work</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Alcohol poisoning</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Animal bite</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Ankle fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Arterial injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Arthropod bite</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Arthropod sting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Brain contusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Burns first degree</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Burns second degree</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Cataract traumatic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Caustic injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Chemical eye injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Chemical injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Chemical poisoning</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Chest injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Compression fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Concussion</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Crushing injury of trunk</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Drug toxicity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Electric shock</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Exposure to toxic agent</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Extradural haematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Eye injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Eye penetration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Face injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Facial bones fracture</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Forearm fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Foreign body in eye</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Gun shot wound</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Hand fracture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Head injury</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Humerus fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Induced abortion haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Injury</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Intentional overdose</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Jaw fracture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Joint dislocation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Joint injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Laceration</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Ligament rupture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Limb crushing injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Limb injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Limb traumatic amputation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Medical device complication</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Multiple fractures</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Multiple injuries</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Muscle injury</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Muscle strain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Near drowning</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Open fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Open wound</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Overdose</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Peripheral nerve injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Pneumothorax traumatic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Post procedural complication</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Post procedural haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Procedural pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Radius fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Renal injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" subjects_affected="322" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="318" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Sciatic nerve injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Skin laceration</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Skull fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Snake bite</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Soft tissue injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Sports injury</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Tendon injury</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Tendon rupture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Thermal burn</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Traumatic brain injury</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Traumatic haematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Traumatic intracranial haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Traumatic shock</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Wrist fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8198"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetes mellitus inadequate control</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Gestational diabetes</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Glucose tolerance impaired in pregnancy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Type 2 diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8198"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Fistula</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Fracture delayed union</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Fracture malunion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Fracture nonunion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Groin pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Myofascial pain syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Osteochondrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Osteonecrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Rhabdomyolysis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Spondylolysis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Synovial cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Systemic lupus erythematosus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8198"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Adenocarcinoma of the cervix</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Angiocentric lymphoma stage II</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Bronchioloalveolar carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Chronic myeloid leukaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Colon cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Fibroadenoma of breast</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Gastric cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Germ cell cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Haemangioma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Lipoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Nasopharyngeal cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Non-Hodgkin's lymphoma stage II</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Oesophageal adenocarcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Ovarian adenoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Pituitary tumour benign</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Salivary gland cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Sarcoma metastatic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Thyroid cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Thyroid neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8198"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Alcoholic seizure</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Cerebral infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Demyelination</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Encephalitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Epilepsy</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Grand mal convulsion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Myelitis transverse</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Optic neuritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Paraplegia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Post-traumatic epilepsy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Tension headache</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Vascular headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="8198"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Abortion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Abortion complete</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Abortion incomplete</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Abortion incomplete complicated</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Abortion missed</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Abortion spontaneous</sub_title>
                <counts group_id="E1" subjects_affected="73" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="54" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Abortion spontaneous complete</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Abortion spontaneous incomplete</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Abortion threatened</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Arrested labour</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Blighted ovum</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Breech presentation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Cephalo-pelvic disproportion</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Complication of pregnancy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Eclampsia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Ectopic pregnancy</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>False labour</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Foetal distress syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Foetal growth retardation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Hydrops foetalis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Hyperemesis gravidarum</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Intra-uterine death</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Labour complication</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Obstructed labour</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Oligohydramnios</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Placenta praevia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Polyhydramnios</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Post abortion haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Postpartum haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Pre-eclampsia</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Pregnancy induced hypertension</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Premature labour</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Premature rupture of membranes</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Premature separation of placenta</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Prolonged labour</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Prolonged pregnancy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Retained placenta or membranes</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Ruptured ectopic pregnancy</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Stillbirth</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Third stage postpartum haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Threatened labour</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Umbilical cord prolapse</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8198"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Acute psychosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Adjustment disorder with depressed mood</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Alcohol withdrawal syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Completed suicide</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Major depression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Psychotic disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Schizophrenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Schizophrenia, paranoid type</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Suicide attempt</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="8198"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Calculus bladder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Calculus ureteric</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Calculus urinary</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Nephrotic syndrome</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Renal failure chronic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Stag horn calculus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Tubulointerstitial nephritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8198"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Adenomyosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Cervical dysplasia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Dysfunctional uterine bleeding</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Dysmenorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Endometriosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Menorrhagia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Ovarian cyst</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Ovarian cyst ruptured</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Ovarian cyst torsion</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Ovarian mass</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Pelvic pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Prostatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Varicocele</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8198"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asphyxia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Bronchitis chronic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Haemothorax</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Hyperventilation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Nasal polyps</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Pneumonia aspiration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8198"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Angioedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Dermatitis allergic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Pemphigus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Pityriasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Psoriasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Rash pruritic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Skin ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="8198"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Social circumstances</title>
            <event_list>
              <event>
                <sub_title>Physical assault</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8198"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Abortion induced</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Caesarean section</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Endometriosis ablation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8198"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypovolaemic shock</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Varicose vein</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8198"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>3.3</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7442" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="6141" subjects_at_risk="8198"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="3677" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="2522" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="5182" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="3410" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Nausea/Vomiting</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="1030" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="802" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="4237" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="2494" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="2177" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="1246" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Oral Temperature</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="1564" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="1009" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Pain/Tenderness</sub_title>
                <description>Local left (ALVAC)</description>
                <counts group_id="E1" subjects_affected="6852" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="3727" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Swelling</sub_title>
                <description>Local left (ALVAC)</description>
                <counts group_id="E1" subjects_affected="2325" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="432" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Arm Movement Limitation</sub_title>
                <description>Local left (ALVAC)</description>
                <counts group_id="E1" subjects_affected="5647" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="2129" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Induration</sub_title>
                <description>Local left (ALVAC)</description>
                <counts group_id="E1" subjects_affected="316" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="108" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Erythema</sub_title>
                <description>Local left (ALVAC)</description>
                <counts group_id="E1" subjects_affected="283" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="177" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Pain/Tenderness</sub_title>
                <description>Local right (AIDSVAX)</description>
                <counts group_id="E1" subjects_affected="3543" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="2991" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Swelling</sub_title>
                <description>Local right (AIDSVAX)</description>
                <counts group_id="E1" subjects_affected="643" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="379" subjects_at_risk="8198"/>
              </event>
              <event>
                <sub_title>Arm Movement Limitation</sub_title>
                <description>Local right (AIDSVAX)</description>
                <counts group_id="E1" subjects_affected="2627" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="1943" subjects_at_risk="8198"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="266" subjects_at_risk="8197"/>
                <counts group_id="E2" subjects_affected="273" subjects_at_risk="8198"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Supachai Rerks-Ngarm</name_or_title>
      <organization>Department of Disease Control, Ministry of Public Health</organization>
      <phone>66-2-590-3006</phone>
      <email>supachai@health.moph.go.th</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

